TD SYNNEX (SNX) Rule 144 notice — 812 shares via Raymond James

Rhea-AI Filing Summary

TD SYNNEX Corporation submitted a Rule 144 notice reporting a proposed sale of 812 common shares through Raymond James & Associates on the NYSE with an aggregate market value of $122,189 and an approximate sale date of 08/13/2025. The filing lists 82,467,079 shares outstanding.

The securities to be sold were acquired as stock grants on 02/28/2022 (364 shares) and 08/31/2022 (448 shares). The form reports no securities sold in the past three months and includes the signer’s representation that they do not know of any material nonpublic information.

Insights

Securities Analyst

TL;DR A small Rule 144 sale of 812 SNX shares is reported; the size is immaterial to the company’s outstanding shares.

The filing documents a brokered sale via Raymond James of 812 common shares with an aggregate market value of $122,189, sourced entirely from 2022 stock grants. Relative to the issuer’s reported 82,467,079 outstanding shares, the proposed sale represents a de minimis percentage, so this notice is unlikely to be material to SNX equity valuation. The filing also states no sales in the past three months, reducing signals of sustained insider liquidation.

Corporate Governance Expert

TL;DR Routine Rule 144 disclosure for shares granted in 2022, with standard representations and broker details; governance impact is minimal.

The report shows the securities were acquired by stock grants and will be sold through a listed broker on the NYSE. The notice contains the customary signer representation regarding absence of undisclosed material information. There are no indications of accelerated or unusual disposition activity and no sales reported in the prior three months, suggesting limited governance or disclosure concerns from this filing alone.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Raymond James & Associates 880 Carillon Parkway St. Petersburg FL 33716	812	122189.00	82467079	08/13/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/28/2022	Stock Grant	Issuer			364	02/28/2022	Stock Grant
Common	08/31/2022	Stock Grant	Issuer			448	08/31/2022	Stock Grant

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the SNX Form 144 report?

The form reports a proposed sale of 812 TD SYNNEX (SNX) common shares via Raymond James with an aggregate market value of $122,189 and approximate sale date 08/13/2025.

Who is the broker handling the sale in the SNX Form 144?

The broker listed is Raymond James & Associates with address at 880 Carillon Parkway, St. Petersburg, FL; the sale is to occur on the NYSE.

How were the 812 SNX shares acquired?

The filing states the shares were acquired as stock grants: 364 shares on 02/28/2022 and 448 shares on 08/31/2022.

Does the Form 144 report any recent sales in the past three months?

The filing indicates Nothing to Report for securities sold during the past three months by the person for whose account the securities are to be sold.

Does the notice include a representation about material nonpublic information?

Yes; the signer represents by signing the notice that they do not know of any material adverse information regarding the issuer that has not been publicly disclosed.